EP3193886A1 - Reducing anxiety in progeny - Google Patents

Reducing anxiety in progeny

Info

Publication number
EP3193886A1
EP3193886A1 EP15794326.7A EP15794326A EP3193886A1 EP 3193886 A1 EP3193886 A1 EP 3193886A1 EP 15794326 A EP15794326 A EP 15794326A EP 3193886 A1 EP3193886 A1 EP 3193886A1
Authority
EP
European Patent Office
Prior art keywords
oligosaccharides
oligosaccharide
digestible oligosaccharide
use according
fructo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15794326.7A
Other languages
German (de)
French (fr)
Inventor
Johan Garssen
Aletta Desiree Kraneveld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Publication of EP3193886A1 publication Critical patent/EP3193886A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

  • the present invention relates to the field of nutrition or nutritional supplements for lactating women, in particular nutrition that provides health benefits for the progeny of the pregnant women after birth thereof.
  • the start of life is a stressful phase and from the moment it is born, an infant can be exposed to all kinds of factors that can influence the infant's state of mind. It can be expected that the mother of a newborn does anything to positively influence the way her baby feels.
  • the present inventors In searching for factors that could be of help as a nutritional support for a breastfeeding or lactating mother to positively influence her baby, the present inventors now surprisingly found that by administering prebiotics to lactating mothers, their progeny displayed reduced anxiety. This was evidenced in a mouse model by a decrease in the vocalisations that were emitted by the progeny in the early stage of life when they were only breast-fed by their mothers, and where the mothers received a diet that was supplemented with prebiotics compared to progeny that were breast-fed by mothers that received a control diet without the prebiotics.
  • the present invention relates to a method for reducing anxiety in a breast-fed infant by administering a non-digestible oligosaccharide to the breastfeeding mother of the infant.
  • the method for reducing anxiety is a non-medical method.
  • the invention can also be worded as the use of a non-digestible oligosaccharide in the manufacture of a composition for reducing anxiety in a breast-fed infant wherein the composition comprising a non-digestible oligosaccharide is administered to the breastfeeding mother of the infant.
  • the invention can also be worded as a non-digestible oligosaccharide for use in reducing anxiety in a breast-fed infant by administering non-digestible oligosaccharide to the breastfeeding mother of the infant.
  • the present method or use involves the administration of a non-digestible oligosaccharide.
  • the non-digestible oligosaccharide in the method or use according to the present invention is preferably (i) not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach) and (ii) fermented by the human intestinal flora, preferably fermentable into organic acids, preferably into lactic acid, butyrate, propionate and/or acetate.
  • sucrose, lactose, maltose and the maltodextrins are considered digestible.
  • the non-digestible oligosaccharide has a DP from 2 to 250, more preferably from 2 to 60.
  • the non- digestible oligosaccharide is at least one, preferably at least two selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, gluco- oligosaccharides, arabino-oligosaccharides, mannan-oligosaccharides, xylo- oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno- oligosaccharides, galactomanno-oligosaccharides sialic acid comprising oligosaccharides and uronic acid oligosaccharides.
  • the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably beta- galacto-oligosaccharides.
  • the group of fructo-oligosaccharides includes inulin
  • the group of galacto-oligosaccharides includes transgalacto- oligosaccharides or beta- galacto-oligosaccharides
  • the group of gluco-oligosaccharides includes gentio-, nigero- and cyclodextrin-oligosaccharides and polydextrose
  • the group of arabinogalacto- oligosaccharides includes gum acacia
  • the group of galactomanno-oligosaccharides includes partially hydrolysed guar gum.
  • the non-digestible oligosaccharide comprises galacto-oligosaccharide.
  • the galacto-oligosaccharide is preferably selected from the group consisting of beta- galacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
  • the non-digestible oligosaccharide comprises beta-galacto- oligosaccharides.
  • Beta-galacto-oligosaccharides as used in the present invention refers to oligosaccharides composed of over 50%, preferably over 65% galactose units based on monomeric subunits, with a degree of polymerization (DP) of 2 to 20, in which at least 50%, more preferably at least 75%, even more preferably at least 90%, of the galactose units are linked together via a beta-glycosidic linkage, preferably a beta- 1,4 glycosidic linkage.
  • the average DP is preferably of 3 to 6.
  • a glucose unit may be present at the reducing end of the chain of galactose units.
  • Beta-galacto- oligosaccharides are sometimes also referred to as transgalacto-oligosacchariodes (TOS).
  • TOS transgalacto-oligosacchariodes
  • a suitable source of beta-galacto-ologosaccharides is Vivinal®GOS (commercially available from Domo Ingredients, Netherlands).
  • Other suitable sources are Oligomate® (Yakult), Cupoligo®, (Nissin) and Bimuno® (Classado).
  • the non-digestible oligosaccharide comprises fructo- oligosaccharide.
  • Fructo-oligosaccharide as used in the present invention refers to oligosaccharides composed of over 50%, preferably over 65 % fructose units based on monomeric subunits, in which at least 50%, more preferably at least 75%, even more preferably at least 90%, of the fructose units are linked together via a beta-glycosidic linkage, preferably a beta-2, 1 glycosidic linkage.
  • a glucose unit may be present at the reducing end of the chain of fructose units.
  • the fructo-oligosaccharide has a DP or average DP of 2 to 250, more preferably 2 to 100, even more preferably 10 to 60.
  • Fructo-oligosaccaride comprises levan, hydrolysed levan, inulin, hydrolysed inulin, and synthesised fructo-oligosaccharides.
  • the non-digestible oligosaccharide comprises short chain fructo-oligosaccharides with an average degree of polymerization (DP) of 3 to 6, more preferably hydrolysed inulin or synthetic fructo- oligosaccharide.
  • the non-digestible oligosaccharide comprises long chain fructo-oligosaccharides with an average DP above 20, such as Orafti HP® (Beneo, Belgium).
  • the composition comprises both short chain and long chain fructo-oligosaccharides.
  • Fructo-oligosaccharide suitable for use in the compositions is also readily commercially available, e.g. Orafti Synergy 1 ® (Beneo, Belgium).
  • the non-digestible oligosaccharide used according to the present invention preferably comprises uronic acid oligosaccharides, more preferably galacturonic acid oligosaccharides.
  • galacturonic acid oligosaccharide refers to an oligosaccharide wherein at least 50% of the monosaccharide units present in the oligosaccharide is galacturonic acid.
  • the galacturonic acid oligosaccharides used in the invention are preferably prepared from degradation of pectin, pectate, and/or polygalacturonic acid.
  • the degraded pectin is prepared by hydrolysis and/or beta-elimination of fruit and/or vegetable pectins, more preferably apple, citrus and/or sugar beet pectin, even more preferably apple, citrus and/or sugar beet pectin degraded by at least one lyase.
  • At least one of the terminal galacturonic acid units of the galacturonic acid oligosaccharide has a double bond.
  • the double bond effectively protects against attachment of pathogenic bacteria to intestinal epithelial cells.
  • one of the terminal galacturonic acid units comprises a C4-C5 double bond.
  • the galacturonic acid oligosaccharide can be derivatised.
  • the galacturonic acid oligosaccharide may be methoxylated and/or amidated.
  • the galacturonic acid oligosaccharides are characterised by a degree of methoxylation above 20%, preferably above 50% even more preferably above 70%.
  • the non-digestible oligosaccharide in the method or use according to the present invention comprises at least beta-galacto-oligosaccharides.
  • the non-digestible oligosaccharide in the method or use according to the present invention comprises at least short chain fructo-oligosaccharides and/or long chain fructo-oligosaccharides, preferably long chain fructo-oligosaccharides.
  • the non-digestible oligosaccharide in the method or use according to the present invention comprises at least uronic acid oligosaccharides.
  • the non-digestible oligosaccharide in the method or use according to the present invention comprises at least beta-galacto-oligosaccharides and at least short chain fructo-oligosaccharides or long chain fructo-oligosaccharides or both. In one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least beta-galacto-oligosaccharides and at least uronic acid oligosaccharides.
  • the non-digestible oligosaccharide in the method or use according to the present invention comprises at least short chain fructo- oligosaccharides and uronic acid oligosaccharides or long chain fructo-oligosaccharides and uronic acid oligosaccharides. In one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least beta-galacto-oligosaccharides and short chain fructo-oligosaccharides and uronic acid oligosaccharides or at least beta-galacto-oligosaccharides and long chain fructo- oligosaccharides and uronic acid oligosaccharides.
  • the non-digestible oligosaccharide in the method or use according to the present invention comprises a mixture of inulin and fructo- oligosaccharides.
  • the non-digestible oligosaccharide in the method or use according to the present invention comprises a mixture of galacto- oligosaccharides and fructo-oligosaccharides selected from the group consisting of short chain fructo-oligosaccharides and inulin, more preferably inulin.
  • the non-digestible oligosaccharide in the method or use according to the present invention comprises galacto-oligosaccharides with a DP of 2-10 and fructo-oligosaccharides with a DP of 2- 60.
  • the non-digestible oligosaccharide comprises beta-galacto- oligosaccharide, fructo-oligosaccharide and a pectin degradation product.
  • the weight ratio beta-galacto-oligosaccharide : fructo-oligosaccharide : pectin degradation product is preferably (20 to 2) : 1 : (1 to 20), more preferably (12 to 7) : 1 : (1 to 3).
  • the non-digestible oligosaccharide is administered to the lactating mother in a serving comprising from 0.05 to 50 grams non-digestible oligosaccharide, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams.
  • the present method or use preferably comprises the administration of a serving comprising from 0.05 to 50 grams galacto-oligosaccharide plus fructo-oligosaccharide , preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams galacto- oligosaccharide plus fructo-oligosaccharide.
  • the present method or use preferably comprises the administration of a serving comprising from 0.05 to 50 grams galacto- oligosaccharide, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams galacto-oligosaccharide.
  • the present method or use preferably comprises the administration of 0.05 to 50 grams non-digestible saccharide per day, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams per day.
  • the present method or use preferably comprises the administration of 0.05 to 50 grams galacto-oligosaccharide plus fructo-oligosaccharide per day, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams galacto-oligosaccharide plus fructo-oligosaccharide per day.
  • the present method or use preferably comprises the administration of 0.05 to 50 grams galacto- oligosaccharide per day, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 gram, preferably from 1 to 5 grams galacto- oligosaccharide per day.
  • a breastfeeding mother includes a woman who taps breast milk and feeds the tapped breast milk via a bottle to the infant.
  • non-digestible oligosaccharide is administered to the breastfeeding mother of the infant.
  • non-digestible oligosaccharide is administered to the breastfeeding mother from the day the infant is born.
  • administration of non-digestible oligosaccharide to the breastfeeding mother is continued until the day the mother stops breastfeeding completely.
  • the present method or use is of benefit for healthy term born infants.
  • the present method or use is of benefit for infants that are prone to develop anxiety.
  • the non-digestible oligosaccharide may be administered to the lactating women in the form of a bar, a capsule, a tablet, a liquid, or a powder.
  • a powder can be mixed with any type of food or beverage prior to intake thereof.
  • non-digestible oligosaccharide is in the form of a nutritional supplement for the lactating women.
  • the non-digestible oligosaccharide is a powder, packed in sachet comprising 1 to 10 g, more preferably 1.5 to 7 g, most preferably 2 to 5 g non-digestible oligosaccharide.
  • the non-digestible oligosaccharide is administered to a lactating woman in an amount from 0.5 to 50 g per day, preferably from 0.1 to 25 g per day, preferably from 0.5 to 15 g per day, preferably from 1 to 10 g per day, preferably from 1 to 5 g per day, preferably from 3 to 25 g per day, preferably from 6 to 12 g per day.
  • this daily dose is administered in one portion per day.
  • this daily dose is divided over 2 or 3 or 4 portions, which are consumed 2, 3 or 4 times per day, respectively.
  • anxiety is reduced in an infant that receives breast milk from a mother that has ingested non-digestible oligosaccharide.
  • Balb/cByJ mice (Charles River Laboratories, Maastricht, The Netherlands) were housed solitary in plastic cages containing standard chip bedding and free access to food and water. Balb/c mice are known as anti-social mice that display increased anxiety-like behavior compared to other murine models.
  • a 12h light dark cycle was followed (7 AM - 7 PM).
  • the day of birth of the pups is postnatal day 0 (P0).
  • P0 postnatal day 0
  • Ultrasonic distress vocalization of male offspring was measured on P10 to determine anxiety-like behavior.
  • the aluminum bottom of the cylinder was connected to a Julabo F12-ED heating circulator (Sigma-Aldrich; Zwijndrecht, The Netherlands) to maintain the temperature at 19 °C.
  • a pup was separated from the dam and its littermates and placed in the cylinder for three minutes, during which the number of calls, average time of calls and average wavelength of calls were measured. Dam and littermates were housed in the same room during this test.
  • Table 1 Pups lactated by a dam fed with scGOS/lcFOS diet show a reduction in ultrasonic vocalizations
  • Control diet AIN93G

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anxiety is reduced in an infant that receives breast milk from a mother that has ingested non-digestible oligosaccharide.

Description

Reducing anxiety in progeny
Field of the invention
The present invention relates to the field of nutrition or nutritional supplements for lactating women, in particular nutrition that provides health benefits for the progeny of the pregnant women after birth thereof.
Background of the invention
The start of life is a stressful phase and from the moment it is born, an infant can be exposed to all kinds of factors that can influence the infant's state of mind. It can be expected that the mother of a newborn does anything to positively influence the way her baby feels.
With the increasing awareness of mothers that the diet has an influence on the quality of breast milk, there is also an increasing willingness of mothers that breastfeed their babies to rely more and more on nutritional support that would translate into beneficial effects in their babies.
Summary of the invention
In searching for factors that could be of help as a nutritional support for a breastfeeding or lactating mother to positively influence her baby, the present inventors now surprisingly found that by administering prebiotics to lactating mothers, their progeny displayed reduced anxiety. This was evidenced in a mouse model by a decrease in the vocalisations that were emitted by the progeny in the early stage of life when they were only breast-fed by their mothers, and where the mothers received a diet that was supplemented with prebiotics compared to progeny that were breast-fed by mothers that received a control diet without the prebiotics.
Detailed description of the invention
Thus, the present invention relates to a method for reducing anxiety in a breast-fed infant by administering a non-digestible oligosaccharide to the breastfeeding mother of the infant. In one embodiment according to the invention, the method for reducing anxiety is a non-medical method.
The invention can also be worded as the use of a non-digestible oligosaccharide in the manufacture of a composition for reducing anxiety in a breast-fed infant wherein the composition comprising a non-digestible oligosaccharide is administered to the breastfeeding mother of the infant.
The invention can also be worded as a non-digestible oligosaccharide for use in reducing anxiety in a breast-fed infant by administering non-digestible oligosaccharide to the breastfeeding mother of the infant.
Non-digestible oligosaccharides
The present method or use involves the administration of a non-digestible oligosaccharide. The non-digestible oligosaccharide in the method or use according to the present invention is preferably (i) not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach) and (ii) fermented by the human intestinal flora, preferably fermentable into organic acids, preferably into lactic acid, butyrate, propionate and/or acetate. For example, sucrose, lactose, maltose and the maltodextrins are considered digestible.
Preferably, in the method or use according to the present invention, the non-digestible oligosaccharide has a DP from 2 to 250, more preferably from 2 to 60. The non- digestible oligosaccharide is at least one, preferably at least two selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, gluco- oligosaccharides, arabino-oligosaccharides, mannan-oligosaccharides, xylo- oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno- oligosaccharides, galactomanno-oligosaccharides sialic acid comprising oligosaccharides and uronic acid oligosaccharides. Preferably the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably beta- galacto-oligosaccharides. The group of fructo-oligosaccharides includes inulin, the group of galacto-oligosaccharides includes transgalacto- oligosaccharides or beta- galacto-oligosaccharides, the group of gluco-oligosaccharides includes gentio-, nigero- and cyclodextrin-oligosaccharides and polydextrose, the group of arabinogalacto- oligosaccharides includes gum acacia, the group of galactomanno-oligosaccharides includes partially hydrolysed guar gum.
Preferably the non-digestible oligosaccharide comprises galacto-oligosaccharide. The galacto-oligosaccharide is preferably selected from the group consisting of beta- galacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT. In a particularly preferred embodiment the non-digestible oligosaccharide comprises beta-galacto- oligosaccharides. Beta-galacto-oligosaccharides as used in the present invention refers to oligosaccharides composed of over 50%, preferably over 65% galactose units based on monomeric subunits, with a degree of polymerization (DP) of 2 to 20, in which at least 50%, more preferably at least 75%, even more preferably at least 90%, of the galactose units are linked together via a beta-glycosidic linkage, preferably a beta- 1,4 glycosidic linkage. The average DP is preferably of 3 to 6. A glucose unit may be present at the reducing end of the chain of galactose units. Beta-galacto- oligosaccharides are sometimes also referred to as transgalacto-oligosacchariodes (TOS). A suitable source of beta-galacto-ologosaccharides is Vivinal®GOS (commercially available from Domo Ingredients, Netherlands). Other suitable sources are Oligomate® (Yakult), Cupoligo®, (Nissin) and Bimuno® (Classado).
On one embodiment, the non-digestible oligosaccharide comprises fructo- oligosaccharide. Fructo-oligosaccharide as used in the present invention refers to oligosaccharides composed of over 50%, preferably over 65 % fructose units based on monomeric subunits, in which at least 50%, more preferably at least 75%, even more preferably at least 90%, of the fructose units are linked together via a beta-glycosidic linkage, preferably a beta-2, 1 glycosidic linkage. A glucose unit may be present at the reducing end of the chain of fructose units. Preferably the fructo-oligosaccharide has a DP or average DP of 2 to 250, more preferably 2 to 100, even more preferably 10 to 60. Fructo-oligosaccaride comprises levan, hydrolysed levan, inulin, hydrolysed inulin, and synthesised fructo-oligosaccharides. In one embodiment, the non-digestible oligosaccharide comprises short chain fructo-oligosaccharides with an average degree of polymerization (DP) of 3 to 6, more preferably hydrolysed inulin or synthetic fructo- oligosaccharide. In one embodiment, preferably the non-digestible oligosaccharide comprises long chain fructo-oligosaccharides with an average DP above 20, such as Orafti HP® (Beneo, Belgium). Preferably the composition comprises both short chain and long chain fructo-oligosaccharides. Fructo-oligosaccharide suitable for use in the compositions is also readily commercially available, e.g. Orafti Synergy 1 ® (Beneo, Belgium). The non-digestible oligosaccharide used according to the present invention preferably comprises uronic acid oligosaccharides, more preferably galacturonic acid oligosaccharides. The term galacturonic acid oligosaccharide as used in the present invention refers to an oligosaccharide wherein at least 50% of the monosaccharide units present in the oligosaccharide is galacturonic acid. The galacturonic acid oligosaccharides used in the invention are preferably prepared from degradation of pectin, pectate, and/or polygalacturonic acid. Preferably the degraded pectin is prepared by hydrolysis and/or beta-elimination of fruit and/or vegetable pectins, more preferably apple, citrus and/or sugar beet pectin, even more preferably apple, citrus and/or sugar beet pectin degraded by at least one lyase. In a preferred embodiment, at least one of the terminal galacturonic acid units of the galacturonic acid oligosaccharide has a double bond. The double bond effectively protects against attachment of pathogenic bacteria to intestinal epithelial cells. Preferably one of the terminal galacturonic acid units comprises a C4-C5 double bond. The galacturonic acid oligosaccharide can be derivatised. The galacturonic acid oligosaccharide may be methoxylated and/or amidated. In one embodiment the galacturonic acid oligosaccharides are characterised by a degree of methoxylation above 20%, preferably above 50% even more preferably above 70%.
Thus, in one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least beta-galacto-oligosaccharides. In one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least short chain fructo-oligosaccharides and/or long chain fructo-oligosaccharides, preferably long chain fructo-oligosaccharides. In one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least uronic acid oligosaccharides. In one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least beta-galacto-oligosaccharides and at least short chain fructo-oligosaccharides or long chain fructo-oligosaccharides or both. In one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least beta-galacto-oligosaccharides and at least uronic acid oligosaccharides. In one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least short chain fructo- oligosaccharides and uronic acid oligosaccharides or long chain fructo-oligosaccharides and uronic acid oligosaccharides. In one embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises at least beta-galacto-oligosaccharides and short chain fructo-oligosaccharides and uronic acid oligosaccharides or at least beta-galacto-oligosaccharides and long chain fructo- oligosaccharides and uronic acid oligosaccharides.
In a preferred embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises a mixture of inulin and fructo- oligosaccharides. In a preferred embodiment the non-digestible oligosaccharide in the method or use according to the present invention comprises a mixture of galacto- oligosaccharides and fructo-oligosaccharides selected from the group consisting of short chain fructo-oligosaccharides and inulin, more preferably inulin.
In case a mixture of two different non-digestible oligosaccharides is used, preferably a mixture of galacto-oligosaccharides and fructo-oligosaccharide, preferably the weight ratio of the mixture of the two different non-digestible oligosaccharides is between 20 and 0.05, more preferably between 20 and 1. Preferably the non-digestible oligosaccharide in the method or use according to the present invention comprises galacto-oligosaccharides with a DP of 2-10 and fructo-oligosaccharides with a DP of 2- 60. In one embodiment, the non-digestible oligosaccharide comprises beta-galacto- oligosaccharide, fructo-oligosaccharide and a pectin degradation product. The weight ratio beta-galacto-oligosaccharide : fructo-oligosaccharide : pectin degradation product is preferably (20 to 2) : 1 : (1 to 20), more preferably (12 to 7) : 1 : (1 to 3). Preferably, the non-digestible oligosaccharide is administered to the lactating mother in a serving comprising from 0.05 to 50 grams non-digestible oligosaccharide, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams. The present method or use preferably comprises the administration of a serving comprising from 0.05 to 50 grams galacto-oligosaccharide plus fructo-oligosaccharide , preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams galacto- oligosaccharide plus fructo-oligosaccharide. The present method or use preferably comprises the administration of a serving comprising from 0.05 to 50 grams galacto- oligosaccharide, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams galacto-oligosaccharide.
The present method or use preferably comprises the administration of 0.05 to 50 grams non-digestible saccharide per day, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams per day. The present method or use preferably comprises the administration of 0.05 to 50 grams galacto-oligosaccharide plus fructo-oligosaccharide per day, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 grams, preferably from 1 to 5 grams galacto-oligosaccharide plus fructo-oligosaccharide per day. The present method or use preferably comprises the administration of 0.05 to 50 grams galacto- oligosaccharide per day, preferably from 0.1 to 25 grams, preferably from 0.5 to 15 grams, preferably from 1 to 10 gram, preferably from 1 to 5 grams galacto- oligosaccharide per day.
Breastfeeding women
In the context of the present invention a breastfeeding mother includes a woman who taps breast milk and feeds the tapped breast milk via a bottle to the infant. According to the method or use of the present invention, non-digestible oligosaccharide is administered to the breastfeeding mother of the infant. Preferably non-digestible oligosaccharide is administered to the breastfeeding mother from the day the infant is born. Preferably administration of non-digestible oligosaccharide to the breastfeeding mother is continued until the day the mother stops breastfeeding completely.
Infant
The present method or use is of benefit for healthy term born infants. In a preferred embodiment the present method or use is of benefit for infants that are prone to develop anxiety.
Composition
The non-digestible oligosaccharide may be administered to the lactating women in the form of a bar, a capsule, a tablet, a liquid, or a powder. Suitably a powder can be mixed with any type of food or beverage prior to intake thereof.
Preferably non-digestible oligosaccharide is in the form of a nutritional supplement for the lactating women. In one embodiment, the non-digestible oligosaccharide is a powder, packed in sachet comprising 1 to 10 g, more preferably 1.5 to 7 g, most preferably 2 to 5 g non-digestible oligosaccharide.
In the present method or use, preferably the non-digestible oligosaccharide is administered to a lactating woman in an amount from 0.5 to 50 g per day, preferably from 0.1 to 25 g per day, preferably from 0.5 to 15 g per day, preferably from 1 to 10 g per day, preferably from 1 to 5 g per day, preferably from 3 to 25 g per day, preferably from 6 to 12 g per day. Preferably, this daily dose is administered in one portion per day. Preferably, this daily dose is divided over 2 or 3 or 4 portions, which are consumed 2, 3 or 4 times per day, respectively.
Application
According to the present invention anxiety is reduced in an infant that receives breast milk from a mother that has ingested non-digestible oligosaccharide.
In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one". Examples - Prebiotics in diet of lactating dam induces reduced anxiety in offspring
The effects of postnatal dietary intervention with short chain GOS and long chain FOS on, anxiety-like behavior was examined in healthy Balb/cByJ mice.
Pregnant Balb/cByJ mice (Charles River Laboratories, Maastricht, The Netherlands) were housed solitary in plastic cages containing standard chip bedding and free access to food and water. Balb/c mice are known as anti-social mice that display increased anxiety-like behavior compared to other murine models.
A 12h light dark cycle was followed (7 AM - 7 PM). The day of birth of the pups is postnatal day 0 (P0). From P0, n=6 dams were fed a diet enriched with 3% scGOS/lcFOS, and n=9 dams were fed the control diet (AIN93G).
On P21, male offspring was weaned. Two cages of five males per cage were randomly formed from the dams that were fed the GOS/FOS diet and two cages were randomly formed of 5 males per cage from the dams on the AIN93G diet. Furthermore, one cage of six males from dams on the control diet was formed, these mice functioned as interaction mice during the social interaction test. Offspring was provided with the same diet as the dam it came from, forming n=10 male mice on 3% GOS/FOS diet and a total of n=16 male mice on AIN93G diet.
Measurement of separation-induced ultrasonic vocalization
Ultrasonic distress vocalization of male offspring was measured on P10 to determine anxiety-like behavior. An ultrasonic vocalization testing cylinder with a lid in which a microphone (UltraSound Advice, London, United Kingdom) was placed, was connected to an amplifier and a computer with registration software (SonoTrack, Metris B.V.; Hoofddorp, The Netherlands). The aluminum bottom of the cylinder was connected to a Julabo F12-ED heating circulator (Sigma-Aldrich; Zwijndrecht, The Netherlands) to maintain the temperature at 19 °C. A pup was separated from the dam and its littermates and placed in the cylinder for three minutes, during which the number of calls, average time of calls and average wavelength of calls were measured. Dam and littermates were housed in the same room during this test. Statistical methods
Differences between groups were statistically analyzed with an unpaired two-tailed Students t-test. When not normally distributed, data was transformed using the natural logarithm before statistical analysis. Data are shown as average ± SEM, using GraphPad Prism, version 6. Results were considered statistically significant when P < 0.05.
Results
Pups lactated by a dam fed with scGOS/lcFOS diet show a reduction in ultrasonic vocalizations
On P10, ultrasonic distress vocalization was measured to assess anxiety-like behavior. Male pups were individually separated from the dam for 3 minutes, during which the amount of UV calls, average time of a call and the average frequency of a call were measured. The number of calls was significantly reduced in the pups that were lactated by dams on a scGOS/lcFOS diet, compared to mice that were lactated by dams on the control diet, (P = 0.040).
Furthermore, there is a trend that shows a reduction in the average time a call lasts in pups that were lactated by a dam on scGOS/lcFOS diet compared to control animals (P = 0.065).
No significant difference can be seen in the average frequency (Hz) of a call emitted by the different pups.
The results are summarized in table 1 Table 1 : Pups lactated by a dam fed with scGOS/lcFOS diet show a reduction in ultrasonic vocalizations
Control diet: AIN93G These results are indicative that a prebiotic diet during the lactation phase reduces anxiety in the offspring.

Claims

Claims
1. Use of a non-digestible oligosaccharide in the manufacture of a composition for reducing anxiety in a breast-fed infant wherein the composition comprising a non- digestible oligosaccharide is administered to the breastfeeding mother of the infant.
2. The use according to claim 1 wherein the non-digestible oligosaccharide comprises galacto-oligosaccharides, preferably with an average degree of polymerisation from 3 to 6.
3. The use according to any one of the preceding claims wherein the non-digestible oligosaccharide comprises fructo-oligosaccharides, preferably with an average degree of polymerisation above 10, preferably above 20.
4. The use according to any one of the preceding claims wherein the non-digestible oligosaccharide comprises galacto-oligosaccharides and fructo-oligosaccharides, preferably in a weight ratio from 20 : 0.5
5. The use according to any one of the preceding claims, wherein the infant is prone to develop anxiety.
6. The use according to any one of the preceding claims wherein the composition is in the form of a nutritional supplement.
7. The use according to any one of the preceding claims wherein the non-digestible oligosaccharide is administered to the breastfeeding mother from the day the infant is born.
8. The use according to any one of the preceding claims wherein administration of the non-digestible oligosaccharide is continued until the day the mother stops breastfeeding completely. The use according to any one of the preceding claims, wherein the non-digestible oligosaccharide is administered to the breastfeeding mother in an amount from 1 to 12 g per day.
Non medical method for reducing anxiety in a breast-fed infant by administering a non-digestible oligosaccharide to the breastfeeding mother of the infant.
EP15794326.7A 2014-09-15 2015-09-15 Reducing anxiety in progeny Withdrawn EP3193886A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184828 2014-09-15
PCT/NL2015/050636 WO2016043583A1 (en) 2014-09-15 2015-09-15 Reducing anxiety in progeny

Publications (1)

Publication Number Publication Date
EP3193886A1 true EP3193886A1 (en) 2017-07-26

Family

ID=51539200

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15794326.7A Withdrawn EP3193886A1 (en) 2014-09-15 2015-09-15 Reducing anxiety in progeny

Country Status (3)

Country Link
EP (1) EP3193886A1 (en)
CN (1) CN107106582A (en)
WO (1) WO2016043583A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065128A4 (en) * 2019-11-29 2023-12-20 Glycom A/S Mixture of hmos for improving the microbiota of pregnant women

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645472C (en) * 2006-03-10 2015-09-15 N.V. Nutricia Use of non-digestable saccharides for giving an infant the best start after birth
EP2127661A1 (en) * 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
RU2586150C2 (en) * 2012-02-10 2016-06-10 Н.В. Нутриция Additive for mother intended for reinforcing the immune system of a child
WO2013126015A1 (en) * 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
AU2013338705B2 (en) * 2012-11-02 2017-06-15 N.V. Nutricia Synbiotics combination for brain improvement

Also Published As

Publication number Publication date
CN107106582A (en) 2017-08-29
WO2016043583A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
US11135290B2 (en) Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
JP4965444B2 (en) Immunostimulatory infant nutrition
ES2611203T3 (en) Use of sphingomyelin and non-digestible carbohydrates to improve intestinal microbiota
US20120122813A1 (en) Composition containing oligosaccharides for the treatment/prevention of infections
US11559539B2 (en) Human milk oligosaccharide for improving immune fitness
WO2016043583A1 (en) Reducing anxiety in progeny
AU2018431641B2 (en) Nutritional composition for use in the treatment of diarrhea, its preparation and method of treatment
EP4048283A1 (en) Compositions comprising 2&#39;-fucosyllactose to prevent asthma
RU2716214C2 (en) Composition for brain improvement
RU2586150C2 (en) Additive for mother intended for reinforcing the immune system of a child
JP2008237162A (en) Intestinal environment improving composition, sweetening composition and functional food
WO2012044155A1 (en) Fat composition for programming immune response

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171107